Navigation Links
SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
Date:8/7/2008

rcised prior to the effective time of the Merger will terminate. Any issued and outstanding stock options with an exercise price per share less than $3.00 will be converted into the right to receive a payment equal to the product of (1) the excess of $3.00 per share over the exercise price per share of such stock options and (2) the number of shares of SGX common stock subject to such stock options.

The completion of the Merger is subject to the satisfaction or waiver of a number of closing conditions, including, among others, (1) adoption of the Merger Agreement by the holders of a majority of SGX's outstanding common stock, (2) subject to certain exceptions, the absence of any material adverse effect on SGX from and after the date of the Merger Agreement, (3) the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, (4) the absence of any legal prohibitions on the closing of the Merger and (5) subject to certain exceptions, the continued accuracy of SGX's representations and warranties as of the effective time of the Merger.

The special meeting of stockholders to consider and vote upon the proposal to adopt the Merger Agreement and to transact such other business as may properly come before the special meeting (or any adjournment, postponement or continuance thereof) is scheduled for 9:00 a.m., California time, on August 20, 2008, at SGX's corporate headquarters located at 10505 Roselle Street, San Diego, California 92121.

Additional Information

SGX filed a definitive proxy statement with the Securities and Exchange Commission on July 21, 2008 with respect to the proposed merger transaction with Eli Lilly and Company. Before making any voting or investment decision with respect to the merger, investors and stockholders of SGX are urged to read the proxy statement and the other relevant materials carefully in their entirety because they contain important information ab
'/>"/>

SOURCE SGX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
4. Watson Pharmaceuticals Reports Second Quarter 2008 Results
5. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
6. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
7. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
9. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
10. Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
11. Anacor Pharmaceuticals Appoints Dr. Kurt Jarnagin Vice President of Biological Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... TRIANGLE PARK, N.C. , July 14, 2014 ... focused on cloud-based drug design and development, announced ... development program. The company has been granted supercomputing ... of multiple parasitic targets.  Through ... the Argonne Leadership Computing Facility (ALCF), researchers at ...
(Date:7/14/2014)... July 14, 2014 Throughout this ... across the clinical trials space, representing 38 countries ... series entitled “Optimizing Patient Participation in Clinical Trials. ... off with internationally renowned R&D expert, Ken Getz, ... on Reinventing Drug Development through Patient Centricity. , ...
(Date:7/14/2014)... 14, 2014 Minerva Neurosciences (NASDAQ: ... therapies to treat neuropsychiatric diseases and disorders, today announced ... vice president of finance and chief accounting officer, effective ... senior executive with more than 20 years of experience ... science companies. His background includes the management of compliance ...
(Date:7/14/2014)... San Mateo, CA (PRWEB) July 14, 2014 ... groundbreaking CONNECT patient registry platform, announced that ... Becker muscular dystrophies; the Phelan-McDermid Syndrome International ... primary Nephrotic Syndrome—have been awarded contracts by ... part of the creation of a new ...
Breaking Biology Technology:Cloud Pharmaceuticals Granted 1M Hours of Supercomputer Time to Target Orphan Diseases Including Malaria 2Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 2Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 3Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 4Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 5Minerva Neurosciences Announces Appointment Of Frederick W. Ahlholm As VP Of Finance And Chief Accounting Officer 2PatientCrossroads Fuels Development of New National Clinical Research Network 2PatientCrossroads Fuels Development of New National Clinical Research Network 3
... Inc., the,leading developer of stents designed for the ... has closed a $14 million Series,C round of ... Venture,Partners joined with Spray Venture Partners in the ... RiverVest have been appointed to the Tryton,Board of ...
... blood pressure of elderly patients could cut their total,mortality ... by a third,according to a new study presented today ... simultaneously in the New England,Journal of Medicine., LONDON, ... Elderly Trial (HYVET), which is co-ordinated by scientists from,Imperial ...
... discover and develop ... SAN FRANCISCO, March 31 The Immune Tolerance Institute,Inc. ... a Center for Critical Path Immunology to investigate the role ... be managed by,ITI and located initially at Beckman Coulter,s Cellular ...
Cached Biology Technology:Tryton Medical, Inc. Closes $14 Million Financing 2Tryton Medical, Inc. Closes $14 Million Financing 3Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over 2Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over 3Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over 4The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory 2The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory 3
(Date:7/14/2014)... German . , ... development. One classical example is the sequential and rhythmic ... that has been linked to the ticking of an ... now, this patterning process was thought to be determined ... periodically trigger new segment formation. However, this week in ...
(Date:7/14/2014)... MedNet Solutions , a global ... management systems, is pleased to announce that ... on software-as-a-service (SaaS) and Internet-based businesses, has made ... funding, representing the first major outside financing in ... the ongoing growth and development of both MedNet ...
(Date:7/14/2014)... 14, 2014 Research and Markets has ... 2014: Applications for Microfluidic Technologies" report to their offering. ... testing based on microfluidic technology is expected to grow sharply, ... CAGR 2014 - 2019 of 23%. Major diagnostics companies (Alere, ... etc.) have realized the potential of rapid molecular diagnostic testing. ...
Breaking Biology News(10 mins):Timing is not only ticking 2Timing is not only ticking 3Arrowroot Capital Invests $4 Million In MedNet Solutions 2Arrowroot Capital Invests $4 Million In MedNet Solutions 3Applications for Microfluidic Technologies in Point of Care Testing: 2014 Report 2Applications for Microfluidic Technologies in Point of Care Testing: 2014 Report 3
... New evidence suggests that the risk of HIV transmission ... According to a study published in the April ... available online, early infection accounted for nearly half of ... province of Quebec, Canada. , Bluma Brenner, PhD, and ...
... Turn up the white noise, says a team of ... the benefits of noise. Their findings could lead to ... an assistant professor of computer science, Joseph Martin, a ... of biology, are working together to explain the biological ...
... no two brains are alike, they can display a ... sensory input. Scientists at the Max Planck Institute for ... mathematical method to design networks from neural cells which ... their method will assist them in getting closer to ...
Cached Biology News:Risk of HIV transmission highest early in infection 2Noise echoes in cell communications 22 brains -- 1 thought 22 brains -- 1 thought 3
...
Human VEGF R Phycoerythrin Sampler (Cl 89106, 49560, 54733)...
... Beagle serum is collected from fasted Beagle canines ... Available Anticoagulants: N-02: Citrate ... K2EDTA N-08: Potassium Oxalate N-10: ... N-05: ACD N-07: CPD ...
... cDNA Purification Kit is designed to purify double-stranded ... cDNA synthesis and PCR. The process is simple ... to 3 g can be efficiently purified and ... 1) DNA is bound to the Microfilter Cartridge ...
Biology Products: